Kjetil Tasken, MD, PhD, University of Oslo, Oslo, Norway, discusses the implementation of three initiatives in Norway with the aim of developing a widespread precision medicine system. The InPreD initiative gives patients with no other treatment options access to a gene panel test, which is then discussed by a molecular tumor board. Approximately 36% of patients are then either assigned the IMPRESS-Norway clinical trial or given a different treatment opportunity. The IMPRESS-Norway trial is a nation-wide clinical trial investigating a range of novel cancer therapies, treating patients based on results from the national molecular tumor board. The third initiative is CONNECT, which is a consortium of both public and private stakeholders. Prof. Tasken also discusses the future directions for these initiatives. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
